幼年特发性关节炎相关葡萄膜炎:18年人群队列结局
基于北欧四国434例幼年特发性关节炎(JIA)患者的前瞻性队列,18年随访发现96例(22.1%)发生葡萄膜炎,其中12例在随访8至18年间确诊。葡萄膜炎患者中38.8%出现眼部并发症,JIA起病至葡萄膜炎诊断间隔短和抗核抗体阳性是并发症危险因素。作者建议JIA诊断后立即开始葡萄膜炎筛查并持续8年以上,高危患者应早期考虑全身免疫抑制治疗。
要点
- JIA患者18年内葡萄膜炎累积发生率为22.1%,部分病例在8年后才确诊。
- 葡萄膜炎患者中38.8%出现眼部并发症,JIA起病至葡萄膜炎诊断间隔短是危险因素。
- 抗核抗体阳性增加眼部并发症风险,JIA诊断后应立即并持续8年以上筛查葡萄膜炎。
核心结论
- JIA相关葡萄膜炎可在JIA诊断8年后才发生,筛查应持续超过8年。
- JIA起病至葡萄膜炎诊断间隔短及抗核抗体阳性与眼部并发症风险升高相关。
- 高危患者应早期考虑全身免疫抑制治疗以快速控制眼部炎症。
研究设计与样本
- 基于丹麦、芬兰、挪威和瑞典特定地理区域的人群基础、多中心、前瞻性JIA队列。
- 纳入1997年1月至2000年6月间起病的JIA患者,前瞻性随访18年,共434例,其中96例发生葡萄膜炎。
- 由儿科风湿病医生和眼科医生收集临床与实验室数据,并在18年时进行横断面评估。
主要发现
- 434例JIA患者中96例(22.1%)发生葡萄膜炎,其中12例(2.8%)在随访8至18年间确诊。
- 葡萄膜炎患者中49.0%(47/96)使用全身免疫抑制药物,无葡萄膜炎患者中为23.1%(78/338)。
- 18年访视时78例中19例(24.4%)存在活动性葡萄膜炎,80例中31例(38.8%)出现眼部并发症。
- JIA起病至葡萄膜炎诊断间隔短是眼部并发症危险因素(OR 1.4,95%CI 1.1-1.8)。
- 葡萄膜炎先于JIA起病者均发生白内障,青光眼OR为31.5(95%CI 3.6-274);抗核抗体阳性者并发症OR为3.0(95%CI 1.2-7.7)。
关键数值与推荐
- 135只葡萄膜炎患眼中12只(8.9%)视力下降至<6/12,80例JIA-U患者中4例(5.0%)双眼视力<6/12。
临床怎么用
- JIA诊断一旦怀疑或确认,应立即开始葡萄膜炎筛查,并持续超过JIA诊断后8年。
- 对具有眼部并发症高危因素(如JIA起病至葡萄膜炎诊断间隔短、抗核抗体阳性)的患者,应早期考虑全身免疫抑制治疗以快速控制炎症。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To assess the long-term outcome of uveitis in juvenile idiopathic arthritis (JIA). DESIGN: Population-based, multicenter, prospective JIA cohort, with a cross-sectional assessment of JIA-associated uveitis (JIA-U) 18 years after the onset of JIA. PARTICIPANTS: A total of 434 patients with JIA, of whom 96 had uveitis, from defined geographic areas of Denmark, Finland, Norway, and Sweden. METHODS: Patients with onset of JIA between January 1997 and June 2000 were prospectively followed for 18 years. Pediatric rheumatologists and ophthalmologists collected clinical and laboratory data. MAIN OUTCOME MEASURES: Cumulative incidence of uveitis and clinical characteristics, JIA and uveitis disease activity, ocular complications, visual outcome, and risk factors associated with the development of uveitis-related complications. RESULTS: Uveitis developed in 96 (22.1%) of 434 patients with JIA. In 12 patients (2.8%), uveitis was diagnosed between 8 and 18 years of follow-up. Systemic immunosuppressive medication was more common among patients with uveitis (47/96 [49.0%]) compared with patients without uveitis (78/338 [23.1%]). Active uveitis was present in 19 of 78 patients (24.4%) at the 18-year visit. Ocular complications occurred in 31 of 80 patients (38.8%). Short duration between the onset of JIA and the diagnosis of uveitis was a risk factor for developing ocular complications (odds ratio [OR], 1.4; 95% confidence interval [CI], 1.1-1.8). Patients with a diagnosis of uveitis before the onset of JIA all developed cataract and had an OR for development of glaucoma of 31.5 (95% CI, 3.6-274). Presence of antinuclear antibodies (ANAs) was also a risk factor for developing 1 or more ocular complications (OR, 3.0; 95% CI, 1.2-7.7). Decreased visual acuity (VA) <6/12 was found in 12 of 135 eyes (8.9%) with uveitis, and 4 of 80 patients (5.0%) with JIA-U had binocular decreased VA <6/12. CONCLUSIONS: Our results suggest that uveitis screening should start immediately when the diagnosis of JIA is suspected or confirmed and be continued for more than 8 years after the diagnosis of JIA. Timely systemic immunosuppressive treatment in patients with a high risk of developing ocular complications must be considered early in the disease course to gain rapid control of ocular inflammation.
引用
- Rypdal V, Glerup M, Songstad NT, et al. Uveitis in Juvenile Idiopathic Arthritis: 18-Year Outcome in the Population-based Nordic Cohort Study. Ophthalmology. 2020. PMID: 32866542. doi:10.1016/j.ophtha.2020.08.024
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。